CV 0903
Alternative Names: CV0903Latest Information Update: 28 Nov 2023
At a glance
- Originator CureVac
- Class Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Intratumoural)
- 07 Oct 2019 CV 0903 is available for licensing as of 07 Oct 2019. https://www.curevac.com/partnering/
- 07 Oct 2019 Preclinical trials in Solid tumours in Germany (Parenteral)